Chipeaux Caroline, de Person Marine, Burguet Nathalie, Billette de Villemeur Thierry, Rose Christian, Belmatoug Nadia, Héron Sylvie, Le Van Kim Caroline, Franco Mélanie, Moussa Fathi
Lip(Sys)(2), LETIAM, Univ. Paris Sud, Université Paris-Saclay, IUT d'Orsay, Plateau de Moulon, F-91400 Orsay, France.
Lip(Sys)(2), LETIAM, Univ. Paris Sud, Université Paris-Saclay, IUT d'Orsay, Plateau de Moulon, F-91400 Orsay, France.
J Chromatogr A. 2017 Nov 24;1525:116-125. doi: 10.1016/j.chroma.2017.10.038. Epub 2017 Oct 14.
While important advances have been recently achieved in the optimization of lipid classes' separation, information on the specific determination of medium polarity lipids such as sphingolipids (SLs) in highly complex matrices remains fragmentary. In human, disorders of SL metabolism known as sphingolipidoses are a heterogeneous group of inherited disorders affecting primarily the central nervous. Early diagnosis of these conditions is of importance notably when a corrective therapy is available. The diagnosis is generally based on the determination of specific SLs in plasma and red blood cells (RBCs). For instance, glucosylceramide (GL1), glucosylsphingosine (Lyso-GL1), sphingosine (Sph), and sphingosine-1-phosphate (S1P) are proposed as relevant biomarkers for Gaucher disease (GD). Our main objective was to evaluate these biomarker candidates in a cohort of GD patients. However, most of current methods of GL1, Lyso-GL1, Sph, and S1P determination in plasma of GD patients require at least two liquid chromatographic runs. On the other hand, except for GL1 nothing is known concerning the RBC sphingolipid content. Yet, several reversed phase LC-MS methods of SLs separation and/or determination in various media with different sample preparation approaches have been proposed since 2010. Here we focused on stationary phase selection and mobile phase composition as well as on the sample preparation step to optimize and validate an UHPLC-MS/MS method for the simultaneous quantification of the four sphingolipids in both plasma and RBCs. A comparison between seven stationary phases including two RP18, two polar embedded RP18, and three HILIC phases shows that under our conditions polar embedded RP18 phases are the most appropriate for the separation of the four SLs, in terms of efficiency, peak symmetry, and separation time. In the same way, a comparison between a single step extraction with methanol and a liquid-liquid extraction with a mixture of methanol/methyl tert-butyl ether, shows that the latter mixture is the most appropriate for the extraction of SLs in terms of recovery and absence of matrix effect. After validation, this method was applied to the evaluation of the targeted SLs in a cohort of 15 known GD patients. The obtained results show that Lyso-GL1 is the only relevant biomarker in both plasma and RBCs for GD diagnosis. As the proposed method is applicable to the determination in such a highly complex matrices of four SLs with a large difference in polarity, and as the sample preparation procedure is freedom of matrix effects, this method can be easily adapted to a large diversity of samples.
尽管最近在脂质类别分离的优化方面取得了重要进展,但关于在高度复杂基质中特异性测定中极性脂质(如鞘脂类,SLs)的信息仍然支离破碎。在人类中,被称为鞘脂贮积病的鞘脂代谢紊乱是一组异质性遗传性疾病,主要影响中枢神经系统。这些疾病的早期诊断尤为重要,特别是当有纠正性治疗方法时。诊断通常基于血浆和红细胞(RBCs)中特定鞘脂类的测定。例如,葡萄糖神经酰胺(GL1)、葡萄糖神经鞘氨醇(溶血 - GL1)、神经鞘氨醇(Sph)和神经鞘氨醇 - 1 - 磷酸(S1P)被提议作为戈谢病(GD)的相关生物标志物。我们的主要目标是在一组GD患者中评估这些候选生物标志物。然而,目前大多数测定GD患者血浆中GL1、溶血 - GL1、Sph和S1P的方法至少需要两次液相色谱运行。另一方面,除了GL1,关于红细胞鞘脂含量一无所知。然而,自2010年以来,已经提出了几种在不同介质中采用不同样品制备方法进行鞘脂类分离和/或测定的反相LC - MS方法。在这里,我们专注于固定相选择、流动相组成以及样品制备步骤,以优化和验证一种UHPLC - MS/MS方法,用于同时定量血浆和红细胞中的四种鞘脂类。对包括两种RP18、两种极性嵌入RP18和三种HILIC固定相在内的七种固定相进行比较表明,在我们的条件下,就效率、峰对称性和分离时间而言,极性嵌入RP18固定相对四种鞘脂类的分离最为合适。同样,对用甲醇进行的一步萃取和用甲醇/甲基叔丁基醚混合物进行的液 - 液萃取进行比较表明,就回收率和无基质效应而言,后一种混合物最适合鞘脂类的萃取。经过验证后,该方法应用于对一组15名已知GD患者中目标鞘脂类的评估。所得结果表明,溶血 - GL1是血浆和红细胞中用于GD诊断的唯一相关生物标志物。由于所提出的方法适用于在如此高度复杂的基质中测定四种极性差异很大的鞘脂类,并且样品制备程序不受基质效应影响,该方法可以很容易地适用于多种样品。